▶주메뉴 바로가기
▶본문 바로가기
SkyLabs and Chong Kun Dang are initiating sales of ring-type heart monitoring device CART-I for the mass market starting December, SkyLabs announced on Nov. 23. Chong Kun Dang has paid SkyLabs 2.5 billion won ($2.2 million) to SkyLabs for the rights to business-to-consumer sales of the CART-I car...
The US’ International Trade Commission on Nov. 20 once again delayed its final ruling on a trade secret suit between Korean companies Medytox and Daewoong involving a botulinum toxin strain. The ITC did not elaborate on the reason for the postponement, but the agency‘s website indicates that t...
Sartorius, a German life sciences company with 170 years of history, announced on Nov. 12 that it will invest $100 million in Korea’s bio cluster of Songdo in Incheon to build a manufacturing facility for biologics plant parts. Sartorius’ decision is largely attributable to Korea’s leading bio...
Biopharmaceutical firm Samsung Biologics unveiled its first research and development center for contract development in the biotechnology hub in southern San Francisco on Thursday. The contract development organization is designed to serve clients -- mostly biopharmaceutical firms there -- to offe...
Enzychem Lifesciences’ COVID-19 treatment candidate EC-18 was granted by the US’ Food and Drug Administration to carry out phase 2 clinical trial on confirmed patients, the company said on August 7. In this phase 2 clinical trial, Enzychem Lifesciences will confirm the therapeutic effects of EC...
GC Pharma on July 29 sought the Drug Ministry’s approval to carry out a phase 2 clinical trials of its plasma-derived COVID-19 treatment. The company plans to conduct tests of its GC5131A on 60 patients at Samsung Medical Center, Asan Medical Center, Chung-Ang University Hospital, Korea Universi...
SK Group is pushing for another initial public offering of its health care affiliate SK Bioscience, just a month after SK Biopharmaceuticals’ record-breaking stock market entry last month. SK Bioscience, a vaccine developer that was spun-off from SK Chemical in July 2018, will reportedly file fo...
South Korean biopharma giant Celltrion said on July 24 it has launched phase 1 clinical trials of a potential antiviral antibody treatment for COVID-19 patients. The clinical study follows promising preclinical results for the virus treatment candidate and has received approval from the Korean M...
Seegene, a Korean diagnostics company acclaimed for having preemptively developed COVID-19 test kits before the pandemic even reached Korea, has since risen to the second rank on the Kosdaq bourse. The ongoing coronavirus threat has shifted the market positions of companies across industries, wit...
We know this by many names. Poo, feces, stool, turd, excrement. ... The list can grow endless if imaginative children join in. But scatology is not a matter to be lightly regarded, as “gut feelings” take on a literal meaning in health care. Chunlab, a microbiome research firm, on Tuesday launch...
SK Biopharmaceuticals, a drug company researching and developing novel medicines for central nervous system disorders, is set to make a record-breaking initial public offering. On June 24, the second and final day of the company’s subscription-open for individual investors, the proof of means th...
South Korean drug developer SK Biopharmaceuticals is likely to get an early admission to join the Kospi 200 -- a basket of top 200 blue-chip stocks of the nation’s benchmark index Kospi -- possibly only two months after its planned market debut in July, according to local analysts on June 22. If...
Biologics drug developer Celltrion said Wednesday it will accelerate its insulin pen biosimilar development along with medical device manufacturer Poonglim Pharmatech. Celltrion will begin developing the insulin biosimilar this year with aims to commercially launch the product in 2025. Global i...
Samsung Biologics has bagged two contract manufacturing deals worth 468 billion won ($378 million) combined, according to its regulatory filing on May 22. The total value of the latest deals is equal to two-thirds of the company’s revenue for last year at 701 billion won. According to the biop...
Lack of pediatricians causes long lines at children's clinics
Naver upgrades search engine with AI
Retail investors' battery frenzy continues
[Weekender] Luxury labels target teens
Korean food makers win legal fights against Chinese counterfeiters
Hyundai Mobis develops ‘communicative’ headlamp
[Test Drive] Kona Electric flaunts longer range, bigger space
LG starts mass production of EV chargers